From the 4/16/99 company press release, they
project first quater earnings estimates in line with
analysit expectations, which should place them at about 5
cents per share. That is why I bought 2000 shares today
at 6 and 3/4. Also from the press release, they
found 2 lots with high B19 PCR parvovirus, which sounds
relatively benign if over 50% of the people in the US
already have it in their blood. The press release said
they are recalilng 7 lots (1 week production) out of
an abundance of caution, which also sounds OK. The
press release also stated that they intend to test
their "production to date" for high levels of B19 PCR
and assess the need for further product recall. This
must be the problem, as no sooner did I buy at 6 and
3/4 then it went immediatley down to 6. Someone is
panicing, and thus if anyone participates in the conference
call it would be extremely helpful if we could get
feedback as to (1) why they are testing for B19 PCR if
over 50% of the people in the US have it in their
blood and no other plasma is tested for it, especially
if it is essentially benign and (2) what are they
going to do with their production to date if they find
it in all the lots, as they are likely to find it if
over 50% of the people already have it? As I undestand
it, the SD process is not supposed to effect
non-lipid viruses like B19 PCR -- so it is not surprising
that such common non-lipid viruses would be found in
the product. Undoubtedly, it is found in the same
percentage of the VITX plasma as it is found in normal
plasma. So can someone tell me what is going on? Why
should this cause the stock to cave -- is it the word
"safety recall" itself that is precipitating the
sell-off, and if in fact there is no genuine need for a
"safety recall", why is management doing a "safety
recall" when their product is safer than anything else
out there? Should all plasma be recalled -- and can
someone articulate what the cost to the company is going
to be from all this? What does the board think about
this selloff and "safety recall", and if someone
listens to the conference call, will they post what
management says about all this? Thanks.
I believe I recall VITX saying that EPS would be
released this Tuesday. Target is to beat $.05.
the afternoon, VITX will hold a conference call. I
strongly urge all serious investors to attend the call.
you must call Debbie Bailey to get the
number(516-752-7314, ask for investor relations).
site is not ready but will have the address
I don't expect any major EPS news (in the 1st qtr)
but I hope we can show continued improvement to lift
the stock price to a respectable level. The late
Friday selloff was only a couple of hundred shares ( I
know because my buy order only was partially filled at
Interesting questions that I hope
1. When will revenue begin from
2. Status on sales effort of
3. In which quarter will we see major
4. When will Plasma disclaimer in SEC reports be
removed? (the one that keeps saying sales are slower than
5. Status on Fibrin Phase III trials?
Universal Plasma-NDA when and what is the economic
7. Management plans on increasing shareholder
8. When will first milestone on red cells with PALL
9. Date for new web site?
est. why the major jump in 3 rd qtr..will we make
11. Insurance lawsuit..status and the income effect
Again, please attend the
conference call, and always be careful.
The purpose of this post is to inform you of an
emerging Internet company, NASDAQ:TPEG, soon to be
"Internet and Technology Resources" Corporation
TPEG began their transition into the Internet business
approximately ninety days ago and are following a model similar
to CMGI and WCAP. All the below FACTS detail their
progress and can be verified by one of two ways:
By reviewing the company Press Releases over the
last three months:
2) By calling Strategic Capital Consultants (IR) @
In addition, a TPEG(IATR) chat room was created last
month to discuss the developments of TPEG. Feel free to
visit that room and ask any questions as they relate to
Or visit the Yahoo message Board
TPEG (IATR) Facts:
1) On January 20, 1999, TPEG
formally announced a corporate restructuring plan to
redirect its business from the movie production industry
to the internet / e-commerce industry.
February 4, 1999, TPEG announced the purchase of a
significant equity position in flowersandgifts.com. The
flowersandgifts.com private placement ends 4-15-99 and an IPO follows
shortly. Their website can be found at:
3) On February 25, 1999, TPEG announced the purchase
of a significant equity position in Pacific
Softworks. Their web site can be found at:
4) On March 1, 1999, TPEG announced that it will
change its name to "Internet and Technology Resources"
(IATR). The name change and cusip change will go into
effect immediately after the shareholder's meeting in
late May 1999.
I am new to this board.
What is VITX's
long-term business outlook?
Are there any current
earnings estimates for this fiscal year?
competiting technology a concern for this company? Could
someone come out with a cheaper alternative such as a
cheap way to test for AIDS, Hepatitis, etc (then the
blood could be simply discarded and no blood would
actually need to be "treated").
<<Is competiting technology a concern for
this company? Could someone come out with a cheaper
such as a cheap way to test for AIDS, Hepatitis,
etc (then the blood could be simply discarded and no
would actually need to be "treated").
I would presume that there are many companies that
have made assay products for such viruses. As for
their cost, that may be expensive but I am not sure how
much a treatment for the VITX product costs. I would
think that much of this may depend on analysis time.
Many assays take some time for the chemical to
register the existance of the virus. Such time cost and
labor cost of looking over each container of blood may
be very costly compared to VITX's treatment (I am
not sure about this).
The other point that
was mentioned in a previous post is that most assays
focus on a specific virus. To check for all known
deseases, one may end up performing several tests (unless
some company comes out with an array of assays on a
single solid phase). If VITX's product can universally
eliminate any type of virus (I have no idea if they can)
then it would again be a peace if mind and a liability
thing. which goes beyond cost. I would like to know just
how well the PLAS-D (or whatever its called)
As for the earning estimates, I
would presume that you can find that in the Yahoo
section under "research", which gives the estimates by
the few analysts that follow this company.
thing I would like to know is that if light is so
destructive to the viruses, cant one just store the blood
bags in a lighted storage for some time to kill off
the viruses or does this also decimate the blood
cells as well?